Atrial fibrillation (AFib), the most common heart rhythm disorder, continues to rise globally - it is predicted to affect more than 12 million people in the US by 2030 and almost 18 million people in Europe by 2060. With a growing aging population and an increased prevalence of heart disease, the demand for effective treatments for AFib is higher than ever before. 

Cardiologists, cardiac surgeons and cardiology APPs all earned more in 2024 than 2023, according to a new survey. Compensation in private practices continues to be much lower than it is integrated practices. 

Stereotaxis and CardioFocus are collaborating on a new robotic pulsed field ablation system. After completing some initial research, the companies are now working toward the launch of a clinical trial. 

"PET has changed the practice of nuclear medicine in general and I think it is going to revitalize the practice of cardiology,"  Marcelo Di Carli, MD, told Cardiovascular Business. He noted that more practices seem interested in implementing PET than ever before.

When patients require PCI and TAVR, performing them at the same time is associated with both short- and long-term benefits. 

Different subtypes of depression are association with specific cardiometabolic diseases, according to new data out of the Netherlands. 

When a 50-year-old patient developed severe TR just months after receiving a heart transplant, the safest treatment option was to implant an Evoque TTVR device. 

TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.

The FDA listened to physician feedback and updated its labeling requirements for fenofibrates. These drugs have not been linked to any significant cardiovascular benefits, and clinicians should act accordingly.